After asthma: redefining airways diseases

Ian D. Pavord; Richard Beasley; Alvar Agusti; Gary P. Anderson; Elisabeth Bel; Guy Brusselle; Paul Cullinan; Adnan Custovic; Francine M. Ducharme; John V. Fahy; Urs Frey; Peter Gibson; Liam G. Heaney; Patrick G. Holt; Marc Humbert; Clare M. Lloyd; Guy Marks; Fernando D. Martinez; Peter D. Sly; Erika von Mutius; Sally Wenzel; Heather J. Zar; Andy Bush

doi:10.1016/S0140-6736(17)30879-6

After asthma: redefining airways diseases

Ian D. Pavord, Richard Beasley, Alvar Agusti, Gary P. Anderson, Elisabeth Bel, Guy Brusselle, Paul Cullinan, Adnan Custovic, Francine M. Ducharme, John V. Fahy, Urs Frey, Peter Gibson, Liam G. Heaney, Patrick G. Holt, Marc Humbert, Clare M. Lloyd, Guy Marks, Fernando D. Martinez, Peter D. Sly, Erika von MutiusSally Wenzel, Heather J. Zar, Andy Bush

Research output: Contribution to journal › Review article › peer-review

503 Scopus citations

Original language	English (US)
Pages (from-to)	350-400
Number of pages	51
Journal	The Lancet
Volume	391
Issue number	10118
DOIs	https://doi.org/10.1016/S0140-6736(17)30879-6
State	Published - Jan 27 2018

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.1016/S0140-6736(17)30879-6

Cite this

Pavord, I. D., Beasley, R., Agusti, A., Anderson, G. P., Bel, E., Brusselle, G., Cullinan, P., Custovic, A., Ducharme, F. M., Fahy, J. V., Frey, U., Gibson, P., Heaney, L. G., Holt, P. G., Humbert, M., Lloyd, C. M., Marks, G., Martinez, F. D., Sly, P. D., ... Bush, A. (2018). After asthma: redefining airways diseases. The Lancet, 391(10118), 350-400. https://doi.org/10.1016/S0140-6736(17)30879-6

After asthma : redefining airways diseases. / Pavord, Ian D.; Beasley, Richard; Agusti, Alvar; Anderson, Gary P.; Bel, Elisabeth; Brusselle, Guy; Cullinan, Paul; Custovic, Adnan; Ducharme, Francine M.; Fahy, John V.; Frey, Urs; Gibson, Peter; Heaney, Liam G.; Holt, Patrick G.; Humbert, Marc; Lloyd, Clare M.; Marks, Guy; Martinez, Fernando D.; Sly, Peter D.; von Mutius, Erika; Wenzel, Sally; Zar, Heather J.; Bush, Andy.

In: The Lancet, Vol. 391, No. 10118, 27.01.2018, p. 350-400.

Research output: Contribution to journal › Review article › peer-review

Pavord, ID, Beasley, R, Agusti, A, Anderson, GP, Bel, E, Brusselle, G, Cullinan, P, Custovic, A, Ducharme, FM, Fahy, JV, Frey, U, Gibson, P, Heaney, LG, Holt, PG, Humbert, M, Lloyd, CM, Marks, G, Martinez, FD, Sly, PD, von Mutius, E, Wenzel, S, Zar, HJ & Bush, A 2018, 'After asthma: redefining airways diseases', The Lancet, vol. 391, no. 10118, pp. 350-400. https://doi.org/10.1016/S0140-6736(17)30879-6

Pavord, Ian D. ; Beasley, Richard ; Agusti, Alvar ; Anderson, Gary P. ; Bel, Elisabeth ; Brusselle, Guy ; Cullinan, Paul ; Custovic, Adnan ; Ducharme, Francine M. ; Fahy, John V. ; Frey, Urs ; Gibson, Peter ; Heaney, Liam G. ; Holt, Patrick G. ; Humbert, Marc ; Lloyd, Clare M. ; Marks, Guy ; Martinez, Fernando D. ; Sly, Peter D. ; von Mutius, Erika ; Wenzel, Sally ; Zar, Heather J. ; Bush, Andy. / After asthma : redefining airways diseases. In: The Lancet. 2018 ; Vol. 391, No. 10118. pp. 350-400.

@article{03f31c004fec49f9a3a7e23234372a96,

title = "After asthma: redefining airways diseases",

author = "Pavord, {Ian D.} and Richard Beasley and Alvar Agusti and Anderson, {Gary P.} and Elisabeth Bel and Guy Brusselle and Paul Cullinan and Adnan Custovic and Ducharme, {Francine M.} and Fahy, {John V.} and Urs Frey and Peter Gibson and Heaney, {Liam G.} and Holt, {Patrick G.} and Marc Humbert and Lloyd, {Clare M.} and Guy Marks and Martinez, {Fernando D.} and Sly, {Peter D.} and {von Mutius}, Erika and Sally Wenzel and Zar, {Heather J.} and Andy Bush",

note = "Funding Information: IDP received grants from GlaxoSmithKline, Afferent and Atopix; and received honoraria and speaker fees from AstraZeneca, Boehringer Ingelheim, Aerocrine, Almirall, Novartis, GlaxoSmithKline, Dey Pharma, Merck Sharp & Dohme, Schering-Plough, Novartis, Napp Pharmaceuticals, Regeneron, Teva, Knopp, Chiesi, and RespiVert. RB received personal fees from the Health Research Council of New Zealand, GlaxoSmithKline, AstraZeneca, and Novartis; and received grants from AstraZeneca, Chiesi, Cephalon, Genentech, GlaxoSmithKline, Novartis, and Sanofi-Aventis. AA received grants and personal fees from AstraZeneca, GlaxoSmithKline, Merck Sharp & Dohme, Menarini, and Novartis; and received personal fees from Teva and Chiesi. GPA serves on advisory boards for Novartis, GlaxoSmithKline, AstraZeneca, Pieris Pharmaceuticals, and Boehringer Ingelheim; and was employed on a sabbatical basis by AstraZeneca between 2015 and 2016. EB received personal fees from Sanofi, Novartis, AstraZeneca, Teva, GlaxoSmithKline, Vectura, and Boehringer Ingelheim; and received grants from GlaxoSmithKline, AstraZeneca, Roche, and Novartis. GB received lecture fees and fees for advisory board membership from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Novartis, Sanofi, Teva, and Zambon. AC received personal fees from Novartis, Sanofi-Regeneron, ALK, Bayer, Thermo Fisher Scientific, GlaxoSmithKline, and Boehringer Ingelheim. FMD received unrestricted donations from Boehringer Ingelheim, Merck Canada, GlaxoSmithKline, and Novartis; received a grant from Merck; and serves on an advisory board for Boehringer Ingelheim, outside the submitted work. JVF received grants from the National Institutes of Health, Pfizer, Genentech, and Vitaeris; received personal fees from Boehringer Ingelheim, Dynavax, Medimmune, Theravance, and Peiris; his institution received a grant from the National Heart, Lung, Blood Institute; and is a named inventor on a patent describing biomarkers of Th2 high asthma and on a patent describing thiol modified carbohydrate compounds as novel mucolytic drugs, which provides no income. PG received grants from National Health and Medical Research Council Australia; and received personal fees from AstraZeneca, GlaxoSmithKline, and Novartis. LGH received grants from MedImmune, Novartis UK, F Hoffmann-La Roche, AstraZeneca, and GlaxoSmithKline; has sat on advisory boards and lectured at meetings supported by GlaxoSmithKline, Respivert, Merck Sharp & Dohme, Nycomed, Boehringer Ingelheim, Vectura, Novartis, and AstraZeneca; has received funding support to attend international respiratory meetings from AstraZeneca, Chiesi, Novartis, Boehringer Ingelheim, and GlaxoSmithKline; received institution fees for participation in asthma clinical trials for GlaxoSmithKline, Schering Plough, Synairgen, and F Hoffmann-La Roche; and is the academic lead for the Stratified Medicine UK Consortium in Severe Asthma, funded by the Medical Research Council, which involves industrial partnerships with Amgen, F Hoffman-La Roche, AstraZeneca, Medimmune, Aerocrine, and Vitalograph. MH received personal fees from Astrazeneca, Novartis, Roche, Sanofi-Regeneron, and Teva; and received grants and personal fees from GlaxoSmithKline. GM received grants from AstraZeneca and GlaxoSmithKline, and received speaker fees from Novartis Pharmaceutical and the International Union Against Tuberculosis and Lung Disease. FDM received grants from the National Institutes of Health, the National Heart, Lung, Blood Institute, the National Institute of Environmental Health Sciences, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health Office of the Director, and Johnson and Johnson; and received personal fees from Copeval and Commense. EvM received personal fees from PharmaVentures, OM Pharma, Decision Resources, Novartis Pharma SAS, The Chinese University of Hong Kong, the University of Copenhagen, HAL Allergie, {\"O}kosoziales Forum Ober{\"o}sterreich, Mundipharma, the American Thoracic Society, AbbVie, the University of Tampere, the European Commission, Massachusetts Medical Society, and the American Academy of Allergy, Asthma and Immunology. SW received grants and personal fees from AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, Genentech, Sanofi-Regeneron, and Novartis; and received personal fees from Knopp. PC, UF, PGH, CML, PDS, HJZ, and AB declare no competing interests. ",

year = "2018",

month = jan,

day = "27",

doi = "10.1016/S0140-6736(17)30879-6",

language = "English (US)",

volume = "391",

pages = "350--400",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier Limited",

number = "10118",

}

TY - JOUR

T1 - After asthma

T2 - redefining airways diseases

AU - Pavord, Ian D.

AU - Beasley, Richard

AU - Agusti, Alvar

AU - Anderson, Gary P.

AU - Bel, Elisabeth

AU - Brusselle, Guy

AU - Cullinan, Paul

AU - Custovic, Adnan

AU - Ducharme, Francine M.

AU - Fahy, John V.

AU - Frey, Urs

AU - Gibson, Peter

AU - Heaney, Liam G.

AU - Holt, Patrick G.

AU - Humbert, Marc

AU - Lloyd, Clare M.

AU - Marks, Guy

AU - Martinez, Fernando D.

AU - Sly, Peter D.

AU - von Mutius, Erika

AU - Wenzel, Sally

AU - Zar, Heather J.

AU - Bush, Andy

N1 - Funding Information: IDP received grants from GlaxoSmithKline, Afferent and Atopix; and received honoraria and speaker fees from AstraZeneca, Boehringer Ingelheim, Aerocrine, Almirall, Novartis, GlaxoSmithKline, Dey Pharma, Merck Sharp & Dohme, Schering-Plough, Novartis, Napp Pharmaceuticals, Regeneron, Teva, Knopp, Chiesi, and RespiVert. RB received personal fees from the Health Research Council of New Zealand, GlaxoSmithKline, AstraZeneca, and Novartis; and received grants from AstraZeneca, Chiesi, Cephalon, Genentech, GlaxoSmithKline, Novartis, and Sanofi-Aventis. AA received grants and personal fees from AstraZeneca, GlaxoSmithKline, Merck Sharp & Dohme, Menarini, and Novartis; and received personal fees from Teva and Chiesi. GPA serves on advisory boards for Novartis, GlaxoSmithKline, AstraZeneca, Pieris Pharmaceuticals, and Boehringer Ingelheim; and was employed on a sabbatical basis by AstraZeneca between 2015 and 2016. EB received personal fees from Sanofi, Novartis, AstraZeneca, Teva, GlaxoSmithKline, Vectura, and Boehringer Ingelheim; and received grants from GlaxoSmithKline, AstraZeneca, Roche, and Novartis. GB received lecture fees and fees for advisory board membership from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Novartis, Sanofi, Teva, and Zambon. AC received personal fees from Novartis, Sanofi-Regeneron, ALK, Bayer, Thermo Fisher Scientific, GlaxoSmithKline, and Boehringer Ingelheim. FMD received unrestricted donations from Boehringer Ingelheim, Merck Canada, GlaxoSmithKline, and Novartis; received a grant from Merck; and serves on an advisory board for Boehringer Ingelheim, outside the submitted work. JVF received grants from the National Institutes of Health, Pfizer, Genentech, and Vitaeris; received personal fees from Boehringer Ingelheim, Dynavax, Medimmune, Theravance, and Peiris; his institution received a grant from the National Heart, Lung, Blood Institute; and is a named inventor on a patent describing biomarkers of Th2 high asthma and on a patent describing thiol modified carbohydrate compounds as novel mucolytic drugs, which provides no income. PG received grants from National Health and Medical Research Council Australia; and received personal fees from AstraZeneca, GlaxoSmithKline, and Novartis. LGH received grants from MedImmune, Novartis UK, F Hoffmann-La Roche, AstraZeneca, and GlaxoSmithKline; has sat on advisory boards and lectured at meetings supported by GlaxoSmithKline, Respivert, Merck Sharp & Dohme, Nycomed, Boehringer Ingelheim, Vectura, Novartis, and AstraZeneca; has received funding support to attend international respiratory meetings from AstraZeneca, Chiesi, Novartis, Boehringer Ingelheim, and GlaxoSmithKline; received institution fees for participation in asthma clinical trials for GlaxoSmithKline, Schering Plough, Synairgen, and F Hoffmann-La Roche; and is the academic lead for the Stratified Medicine UK Consortium in Severe Asthma, funded by the Medical Research Council, which involves industrial partnerships with Amgen, F Hoffman-La Roche, AstraZeneca, Medimmune, Aerocrine, and Vitalograph. MH received personal fees from Astrazeneca, Novartis, Roche, Sanofi-Regeneron, and Teva; and received grants and personal fees from GlaxoSmithKline. GM received grants from AstraZeneca and GlaxoSmithKline, and received speaker fees from Novartis Pharmaceutical and the International Union Against Tuberculosis and Lung Disease. FDM received grants from the National Institutes of Health, the National Heart, Lung, Blood Institute, the National Institute of Environmental Health Sciences, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health Office of the Director, and Johnson and Johnson; and received personal fees from Copeval and Commense. EvM received personal fees from PharmaVentures, OM Pharma, Decision Resources, Novartis Pharma SAS, The Chinese University of Hong Kong, the University of Copenhagen, HAL Allergie, Ökosoziales Forum Oberösterreich, Mundipharma, the American Thoracic Society, AbbVie, the University of Tampere, the European Commission, Massachusetts Medical Society, and the American Academy of Allergy, Asthma and Immunology. SW received grants and personal fees from AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, Genentech, Sanofi-Regeneron, and Novartis; and received personal fees from Knopp. PC, UF, PGH, CML, PDS, HJZ, and AB declare no competing interests.

PY - 2018/1/27

Y1 - 2018/1/27

UR - http://www.scopus.com/inward/record.url?scp=85029208732&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029208732&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(17)30879-6

DO - 10.1016/S0140-6736(17)30879-6

M3 - Review article

C2 - 28911920

AN - SCOPUS:85029208732

VL - 391

SP - 350

EP - 400

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 10118

ER -

After asthma: redefining airways diseases

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this